Acromegaly - 140 Studies Found

Completed : Long Term Study With B2036-PEG
: Acromegaly
: 2005-09-01
: Drug: Pegvisomant
Terminated : Predictive Factors Study
: Acromegaly
: 2013-12-19
: Drug: Somatuline Autogel® (lanreotide) 60, 90, 120 mg. Patients receiving treatment as prescribed b
Completed : Pegvisomant And Sandostatin LAR Combination Study
: Acromegaly
: 2003-09-04
:
  • Drug: Pegvisomant/ Sandostatin LAR
  • Drug: S
Completed : Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
:
  • Acromegaly
  • Neuroendocrine Tumors

: 2014-11-17
: Drug: octreotide FluidCrystal® injection depot Other Name: CAM2029
Completed : Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors
:
  • Acromegaly
  • Nonfunctioning Pituitary Tumor

: 2012-03-29
Active, not recruiting : Somatuline Predictive Factors in Acromegaly and NET
:
  • Acromegaly
  • Neuroendocrine Tumours

: 2013-04-23
: Drug: Somatuline Autogel® 60, 90 or 120 mg
Completed : Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
:
  • Carcinoid Tumor
  • Acromegaly

: 2007-03-09
: Drug: Pasireotide
Completed : Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
: Acromegaly
: 2009-12-07
: Drug: Pre-treatment with octreotide Pre-treatment with octreotide
Completed : Tissue Biomarker for Pegvisomant Action
: Acromegaly
: 2010-12-15
: Drug: Pegvisomant Pegvisomant used as indicated Othe
Terminated : Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
: Acromegaly
: 2008-03-21
:
  • Drug: C2L-OCT-01 PR, 10 or 20 mg

<<< Previous | Next >>>